M
MiMedx Group, Inc. (MDXG)
NCM – Real Time Price. Currency in USD
3.81
-0.13 (-3.30%)
At close: Mar 27, 2026, 4:00 PM EDT
3.91
+0.10 (2.62%)
After-hours: Mar 27, 2026, 5:41 PM EDT
Get all premium features to the best stock analysis tool
NCM – Real Time Price. Currency in USD
3.81
-0.13 (-3.30%)
At close: Mar 27, 2026, 4:00 PM EDT
3.91
+0.10 (2.62%)
After-hours: Mar 27, 2026, 5:41 PM EDT
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company processes the human placental tissues membrane, and umbilical cord and the placental disc utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins, including cytokines, chemokines, and growth factors. Its patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. The company’s wound care products include EPIFIX, EPICORD, EPIXPRESS, CHORIOFIX, EMERGE, CELERA, REGENKIT WOUND GEL, and EPIEFFECT sheets for use as protective barriers that enables a healthcare provider to select an appropriate size graft based on the size of the wound to reduce product waste. Its surgical and other product offerings consist of AMNIOFIX, AMNIOBURN, AMNIOCORD, AXIOFILL, HELIOGEN, and AMNIOEFFECT for applications in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery, and various orthopedic repairs and reconstructions. The company’s products are used in the areas of wound care, burn, and surgical fields in healthcare. It sells its products through direct sales force and independent sales agents, as well as to individual customers and independent distributors in the United States. The company has a strategic alliance with Vaporox, Inc. for the promotion of their wound care offerings. The company was founded in 2006 and is headquartered in Marietta, Georgia.
| Name | Position |
|---|---|
| Dr. David H. Mason Jr., M.D. | Chief Medical Officer |
| Mr. Douglas C. Rice CPA | Chief Financial Officer |
| Mr. Joseph H. Capper | CEO & Director |
| Mr. Mark P. Graves | Senior VP & Chief Compliance Officer |
| Mr. Matthew M. Notarianni | Head of Investor Relations |
| Mr. William F. Hulse IV | General Counsel & Chief Administrative Officer |
| Ms. Hilary Dixon | Vice President of Investor Relations & Corporate Strategic Communications |
| Date | Type | Document |
|---|---|---|
| 2026-01-12 | 8-K | mdxg-20260112.htm |
| 2025-10-29 | 8-K | mdxg-20251029.htm |
| 2025-09-03 | 8-K | mdxg-20250903.htm |
| 2025-07-30 | 8-K | mdxg-20250730.htm |
| 2025-07-28 | S-8 | mdxg-formsx8x2025amendment.htm |
| 2025-06-20 | 8-K | mdxg-20250618.htm |
| 2025-05-23 | DEFA14A | d14157ddefa14a.htm |
| 2025-05-13 | 8-K | mdxg-20250513.htm |
| 2025-04-30 | 10-Q | mdxg-20250331.htm |
| 2025-02-27 | 8-K | mdxg-20250227.htm |
| Ms. Kate Surdez |
| Chief Human Resources Officer |
| Ms. Kimberly Maersk-Moller | Chief Commercial Officer |
| Ms. Ricci S. Whitlow | Executive VP & COO |